GE HealthCare to buy SOFIE Biosciences for $945M

GE HealthCare has agreed to acquire U.S. PET radiopharmaceutical contract manufacturer SOFIE Biosciences from Trilantic North America for $945 million in cash. SOFIE runs 15 sites and 21 cyclotrons across the U.S., giving it the density to deliver fluorine-18 tracers within their 110-minute half-life window.

• Deal valued at $945 million in cash; seller is Trilantic North America
• SOFIE operates 15 sites and 21 cyclotrons across the U.S.
• Fluorine-18 has a 110-minute half-life, limiting delivery to 5–7 hours
• SOFIE already contract-manufactures GE HealthCare's Flyrcado